Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BILN 2061 ZW in Healthy Males
NCT02268760Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2001
- Primary completion
- Sep 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of ciluprevir in hepatitis C (HCV) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with clinically relevant changes in vital signs, Changes from baseline in laboratory tests and 12 more. Started Jun 2001; status: completed.
02
Drugs
ciluprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02268760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268760.